|
|
 |
|
Viewing report
|
|
|
|
Companion Diagnostics in Personalized Medicine and Cancer Therapy
TriMark Publications, April 2008, Pages: 190
A near-term market opportunity for cancer companion diagnostic tests exists in drug selection for cancer therapy. Co-development of molecular diagnostics and targeted therapeutics has already been proven to be a successful strategy in the development of novel anti-cancer drugs. Adoption of biomarker development in clinical research provides great opportunities to identify patient subpopulations with differential drug responses and to uncover the underlying mechanisms. These data could help to explain if clinical trials of new drugs are adequate, and offer the possibility of creating a clear prescription path based on predictive biomarkers.
The purpose of this report is to describe the specific segment of the diagnostics market that develops new technology platforms for evaluating the metabolism of therapeutic agents, or for evaluating which therapeutic regimes are most effective for a particular type of disease. The term companion diagnostic means that the particular diagnostic test under evaluation is specifically linked to a known therapeutic drug. This linkage could be important in the therapeutic application and clinical outcome of a drug (personalized medicine), or an important component of the drug development process. This report focuses on the former linkage, i.e., the use of companion diagnostic tests in personalized medicine.
Also available
Point of Care Diagnostic Testing World Markets
Cancer Diagnostic Testing World Markets
Cancer Diagnostic Testing World Markets
Key Diagnostic Testing Markets
Women’s Health Diagnostic Testing
Molecular Diagnostics Markets
Cardiac Marker Diagnostic Testing Markets
High-Growth Diagnostic Testing Markets
Point of Care Diagnostic Testing Sector Trends
Biomarker Technology Platforms for Cancer Diagnoses and Therapies
Cancer Cell Therapy Markets
Cancer Therapeutics Markets
Cytology and HPV Testing World Markets
Cancer Bundle
Diagnostics Bundle
Customers who bought this item also bought
Personalized Medicine
Cancer Personalized Medicine 2008
Personalized Medicine - Scientific and Commercial Aspects
Companion Biomarkers in Drug Development
MicroRNA Diagnostics, Therapeutics, and Cancer Personalized Medicine 2009 Market Report
Disruption or Advantage? Update on Companion Diagnostics
Companion Diagnostics: Enabling Personalized Medicines in Cancer
It's All About the Biomarkers: How 2008's Biomarker-Based Partnering Is Driving Personalized Medicine
The Trend Toward Personalized Medicine
Molecular Diagnostics - Technologies, Markets and Companies
The Landscape of Companion Diagnostics: Challenges, Opportunities, and Future Trends
Molecular Diagnostics Markets
|
|
|
|
